Private Market View

Cleerly

Decision/Risk Analysis · Denver, CO · Founded 2016 · Privately Held (backing)

PA Mark · $/share
$12
Sep 2026
Implied valuation
Total raised
$410.3M
Last round
Later Stage VC
Nov 2024

Key facts

as of Sep 2026
  • It has raised $410.3M across 2 recorded rounds; the latest was Later Stage VC ($51.3M) in Nov 2024.
  • Notable investors include General Catalyst, Impact Assets, Insight Partners (New York), Fidelity Management & Research Company, Battery Ventures23 tracked in total.
  • 3 institutional filers report fund marks on Cleerly across 15 filings.
  • Cleerly has filed 1 Form D with the SEC, most recently Dec 2024 ($51.3M sold to 10 investors).
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$12per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 2 inputs:N-PORT marks 100%
Free account
See the evidence behind this price
  • ·Post-money valuations for all 2 rounds
  • ·The complete investor list — 23 names
  • ·Watchlist + deal alerts for Cleerly
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Cleerly shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

3 filers · latest Jun 2026

3 SEC-registered funds reported 15 fair-value marks on Cleerly between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.

Funding rounds

2 rounds
Nov 2024Later Stage VC$51.3MSEC filing
Jul 2022Later Stage VC (Series C)$230.0M

About Cleerly

Developer of a healthcare platform designed to create a new standard of care for coronary artery disease. The company's platform has a non-invasive approach that supports the understanding of plaques and offers quantification and characterization of plaque buildup in the heart arteries, enabling healthcare providers to drastically improve the identification of at-risk patients for early treatment and prevention of heart attacks cost-effectively.

Industry
Decision/Risk Analysis
Sector
Healthcare
HQ
Denver, CO, United States
Founded
2016
Employees
235
Ownership
Privately Held (backing)